These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37622126)

  • 21. Autoantibodies against Endothelin 1 Type A Receptor Are Strong Predictors of Digital Ulcers in Systemic Sclerosis.
    Avouac J; Riemekasten G; Meune C; Ruiz B; Kahan A; Allanore Y
    J Rheumatol; 2015 Oct; 42(10):1801-7. PubMed ID: 26233500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibodies against angiotensin II type 1 receptor (AT1R) and endothelin receptor type A (ETAR) in systemic sclerosis (SSc)-response.
    Riemekasten G; Cabral-Marques O
    Autoimmun Rev; 2016 Sep; 15(9):935. PubMed ID: 27074525
    [No Abstract]   [Full Text] [Related]  

  • 23. Serum levels for midkine, a heparin-binding growth factor, inversely correlate with angiotensin and endothelin receptor autoantibody titers in patients with macroangiopathy.
    Salaru DL; Albert C; Königsmark U; Brandt S; Halloul Z; Heller A; Heidecke H; Dragun D; Mertens PR
    Int Angiol; 2014 Aug; 33(4):372-8. PubMed ID: 25056169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vascular hypothesis revisited: Role of stimulating antibodies against angiotensin and endothelin receptors in the pathogenesis of systemic sclerosis.
    Cabral-Marques O; Riemekasten G
    Autoimmun Rev; 2016 Jul; 15(7):690-4. PubMed ID: 26970493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis.
    Kill A; Tabeling C; Undeutsch R; Kühl AA; Günther J; Radic M; Becker MO; Heidecke H; Worm M; Witzenrath M; Burmester GR; Dragun D; Riemekasten G
    Arthritis Res Ther; 2014 Jan; 16(1):R29. PubMed ID: 24472528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Agonistic antibodies in systemic sclerosis.
    Moroncini G; Svegliati Baroni S; Gabrielli A
    Immunol Lett; 2018 Mar; 195():83-87. PubMed ID: 29032187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of endothelial dysfunction in the severity of COVID‑19 infection (Review).
    Kadiyska T; Tourtourikov I; Dabchev K; Cherneva R; Stoynev N; Hadjiolova R; Mitev V; Spandidos DA; Adamaki M; Zoumpourlis V
    Mol Med Rep; 2022 Nov; 26(5):. PubMed ID: 36196882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin II enhances endothelin-1-induced vasoconstriction through upregulating endothelin type A receptor.
    Lin YJ; Kwok CF; Juan CC; Hsu YP; Shih KC; Chen CC; Ho LT
    Biochem Biophys Res Commun; 2014 Aug; 451(2):263-9. PubMed ID: 25088996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-AT1R autoantibodies and prediction of the severity of Covid-19.
    Papola F; Biancofiore V; Angeletti C; Grimaldi A; Carucci AC; Cofini V; Necozione S; Rosciano A; Marinangeli F; Cervelli C
    Hum Immunol; 2022 Feb; 83(2):130-133. PubMed ID: 34772541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term follow-up of non-HLA and anti-HLA antibodies: incidence and importance in renal transplantation.
    Banasik M; Boratyńska M; Kościelska-Kasprzak K; Mazanowska O; Bartoszek D; Zabińska M; Myszka M; Nowakowska B; Hałoń A; Szyber P; Patrzałek D; Klinger M
    Transplant Proc; 2013 May; 45(4):1462-5. PubMed ID: 23726597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AT2R autoantibodies block angiotensin II and AT1R autoantibody-induced vasoconstriction.
    Liles C; Li H; Veitla V; Liles JT; Murphy TA; Cunningham MW; Yu X; Kem DC
    Hypertension; 2015 Oct; 66(4):830-5. PubMed ID: 26259590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin II Type I Receptor (AT1R): The Gate towards COVID-19-Associated Diseases.
    El-Arif G; Khazaal S; Farhat A; Harb J; Annweiler C; Wu Y; Cao Z; Kovacic H; Abi Khattar Z; Fajloun Z; Sabatier JM
    Molecules; 2022 Mar; 27(7):. PubMed ID: 35408447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin II receptor agonist antibodies are associated with microvascular damage in lupus nephritis.
    Mejia-Vilet JM; López-Hernández YJ; Santander-Vélez JI; Trujeque-Matos M; Cruz C; Carranza de la Torre CA; Espinosa-Cruz V; Espinosa-González R; Uribe-Uribe NO; Morales-Buenrostro LE
    Lupus; 2020 Apr; 29(4):371-378. PubMed ID: 32041505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autoantibodies Targeting G-Protein-Coupled Receptors: Pathogenetic, Clinical and Therapeutic Implications in Systemic Sclerosis.
    Binda M; Moccaldi B; Civieri G; Cuberli A; Doria A; Tona F; Zanatta E
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiotensin II receptor I auto-antibodies following SARS-CoV-2 infection.
    Jiang Y; Duffy F; Hadlock J; Raappana A; Styrchak S; Beck I; Mast FD; Miller LR; Chour W; Houck J; Armistead B; Duvvuri VR; Yeung W; Haglund M; Wallner J; Wallick JA; Hardy S; Oldroyd A; Ko D; Gervassi A; Murray KM; Kaplan H; Aitchison JD; Heath JR; Sather DN; Goldman JD; Frenkel L; Harrington WE
    PLoS One; 2021; 16(11):e0259902. PubMed ID: 34788328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of angiotensin II type 1 receptor antibodies on post-heart transplantation outcome in Heart Mate II bridged recipients.
    Urban M; Slavcev A; Gazdic T; Ivak P; Besik J; Netuka I
    Interact Cardiovasc Thorac Surg; 2016 Mar; 22(3):292-7. PubMed ID: 26675563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vascular and Non-HLA autoantibody profiles in hospitalized patients with COVID-19.
    Lichtenstein B; Zheng Y; Gjertson D; Ferbas KG; Rimoin AW; Yang OO; Aldrovandi GM; Schaenman JM; Reed EF; Fulcher JA
    Front Immunol; 2023; 14():1197326. PubMed ID: 37398658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes.
    Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Bartoszek D; Zabińska M; Myszka M; Zmonarski S; Protasiewicz M; Nowakowska B; Hałoń A; Chudoba P; Klinger M
    Transpl Int; 2014 Oct; 27(10):1029-38. PubMed ID: 24909812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pre-transplant AT
    Gareau AJ; Wiebe C; Pochinco D; Gibson IW; Ho J; Rush DN; Nickerson PW
    Transpl Immunol; 2018 Feb; 46():29-35. PubMed ID: 29217423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.